Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.